Sofiva Genomics Co.,Ltd. (TPEX:6615)
Taiwan · Delayed Price · Currency is TWD 32.80
-0.15 (-0.46%)
Nov 6, 2026, 1:02 PM CST
Sofiva Genomics Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 708 | 651 | 863 | 876 | 784 | 1,042 | |
Market Cap Growth | 3.47% | -24.53% | -1.51% | 11.72% | -24.75% | -4.66% |
Enterprise Value | 615 | 579 | 784 | 798 | 684 | 906 |
Last Close Price | 32.80 | 30.15 | 39.60 | 40.53 | 35.37 | 45.11 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 102.43 | - | 46.81 | 75.98 | 18.33 | 18.29 |
Forward PE | - | 12.19 | 12.19 | 12.19 | 12.09 | 18.13 |
PS Ratio | 1.87 | 1.69 | 1.90 | 1.88 | 1.58 | 2.05 |
PB Ratio | 1.09 | 1.04 | 1.34 | 1.42 | 1.25 | 1.67 |
P/TBV Ratio | 1.10 | 1.05 | 1.36 | 1.43 | 1.26 | 1.69 |
P/FCF Ratio | 25.16 | 45.85 | 48.54 | 325.36 | - | 14.49 |
P/OCF Ratio | 23.31 | 42.40 | 24.87 | 36.96 | 45.75 | 13.01 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.62 | 1.50 | 1.73 | 1.71 | 1.38 | 1.78 |
EV/EBITDA Ratio | 10.87 | - | 34.89 | 78.13 | 22.91 | 15.00 |
EV/EBIT Ratio | 39.59 | - | - | - | 180.55 | 25.71 |
EV/FCF Ratio | 21.84 | 40.79 | 44.10 | 296.41 | - | 12.60 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.06 | 0.06 | 0.08 | 0.10 | 0.12 | 0.14 |
Debt / EBITDA Ratio | 1.71 | 4.52 | 1.40 | 2.50 | 1.60 | 1.11 |
Debt / FCF Ratio | 1.36 | 2.50 | 3.00 | 23.62 | - | 1.20 |
Net Debt / Equity Ratio | -0.14 | -0.14 | -0.14 | -0.12 | -0.15 | -0.25 |
Net Debt / EBITDA Ratio | -10.50 | 12.59 | -4.13 | -7.48 | -3.23 | -2.64 |
Net Debt / FCF Ratio | -3.31 | -6.28 | -5.22 | -28.40 | 5.87 | -2.21 |
Asset Turnover | 0.51 | 0.52 | 0.59 | 0.59 | 0.61 | 0.65 |
Inventory Turnover | 7.76 | 7.05 | 7.20 | 6.82 | 7.03 | 7.24 |
Quick Ratio | 3.03 | 2.70 | 2.60 | 2.34 | 2.19 | 2.63 |
Current Ratio | 3.54 | 3.33 | 3.27 | 2.88 | 2.79 | 3.03 |
Return on Equity (ROE) | 2.30% | -1.39% | 3.03% | 1.91% | 6.89% | 9.64% |
Return on Assets (ROA) | -1.57% | -2.83% | -0.27% | -1.26% | 0.29% | 2.80% |
Return on Invested Capital (ROIC) | -2.67% | -6.19% | -0.50% | -2.96% | 0.69% | 6.98% |
Return on Capital Employed (ROCE) | -2.80% | -5.20% | -0.50% | -2.40% | 0.50% | 5.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 5, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.98% | -1.44% | 2.14% | 1.32% | 5.46% | 5.47% |
FCF Yield | 3.97% | 2.18% | 2.06% | 0.31% | -2.09% | 6.90% |
Dividend Yield | - | - | 0.75% | 0.49% | 2.73% | 4.10% |
Payout Ratio | 45.54% | - | 23.18% | 185.32% | 99.88% | 52.24% |
Buyback Yield / Dilution | -0.03% | 0.23% | -1.28% | 0.04% | -0.40% | 0.43% |
Total Shareholder Return | -0.03% | 0.23% | -0.53% | 0.53% | 2.32% | 4.53% |